BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis Study

Reuters03-30

March 30 (Reuters) - Connect Biopharma Holdings Ltd CNTB.O:

RADEMIKIBART DEMONSTRATES BEST-IN-CLASS POTENTIAL IN PHASE 3 ATOPIC DERMATITIS STUDY
CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART ACHIEVES RAPID, DURABLE EFFICACY IN PHASE 3 ATOPIC DERMATITIS STUDY THROUGH 52 WEEKS
CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART WELL TOLERATED WITH SAFETY COMPARABLE TO PLACEBO

Source text: ID:nGNX7tTRPs

Further company coverage: CNTB.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623343620?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623343620","market":"fut","top_or_hot":-1,"title":"BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis Study</title></head><body><p><span>March 30 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Holdings Ltd <span>CNTB.O</span>:</p><ul><li><p>RADEMIKIBART DEMONSTRATES BEST-IN-CLASS POTENTIAL IN PHASE 3 ATOPIC DERMATITIS STUDY</p></li><li><p>CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART ACHIEVES RAPID, DURABLE EFFICACY IN PHASE 3 ATOPIC DERMATITIS STUDY THROUGH 52 WEEKS</p></li><li><p>CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART WELL TOLERATED WITH SAFETY COMPARABLE TO PLACEBO</p></li></ul><p>Source text: <span>ID:nGNX7tTRPs</span></p><p>Further company coverage: <span>CNTB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis Study</title></head><body><p><span>March 30 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a> Holdings Ltd <span>CNTB.O</span>:</p><ul><li><p>RADEMIKIBART DEMONSTRATES BEST-IN-CLASS POTENTIAL IN PHASE 3 ATOPIC DERMATITIS STUDY</p></li><li><p>CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART ACHIEVES RAPID, DURABLE EFFICACY IN PHASE 3 ATOPIC DERMATITIS STUDY THROUGH 52 WEEKS</p></li><li><p>CONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART WELL TOLERATED WITH SAFETY COMPARABLE TO PLACEBO</p></li></ul><p>Source text: <span>ID:nGNX7tTRPs</span></p><p>Further company coverage: <span>CNTB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNTB","symbol_name":"康乃德生物医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I0MV:1","article_id":"2623343620","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623343620","pubTimestamp":1774876843,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis StudyMarch 30 (Reuters) - Connect Biopharma Holdings Ltd CNTB.O:RADEMIKIBART DEMONSTRATES BEST-IN-CLASS POTENTIAL I","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNTB":"康乃德生物医药","BK4139":"生物科技"},"translate_title":"简介-Rademikibart在3期特应性皮炎研究中展现出同类最佳的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTB":0.9},"content_text":"BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis StudyMarch 30 (Reuters) - Connect Biopharma Holdings Ltd CNTB.O:RADEMIKIBART DEMONSTRATES BEST-IN-CLASS POTENTIAL IN PHASE 3 ATOPIC DERMATITIS STUDYCONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART ACHIEVES RAPID, DURABLE EFFICACY IN PHASE 3 ATOPIC DERMATITIS STUDY THROUGH 52 WEEKSCONNECT BIOPHARMA HOLDINGS LTD - RADEMIKIBART WELL TOLERATED WITH SAFETY COMPARABLE TO PLACEBOSource text: ID:nGNX7tTRPsFurther company coverage: CNTB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623343620","isCrawlerRequest":true}